The FDA Just Showed Its Hand on CBD -- Is It Time for Investors to Fold?


Few industries are expected to offer growth potential that's as impressive as the cannabis industry over the next decade. But contained within the pot industry is a niche trend that's growing considerably faster than the overall marijuana industry: cannabidiol (CBD).

The hottest trend in cannabis: Cannabidiol

As some of you may be aware, cannabidiol is one of the two most popular cannabinoids, with the other being tetrahydrocannabinol (THC). THC is predominantly found in the cannabis plant, and it's the cannabinoid responsible for getting users high. Meanwhile, CBD can be found in the cannabis or hemp plants (very small quantities of THC are also found in hemp plants), with hemp being a considerably easier-to-grow and less costly plant, making it the preferred choice for CBD extraction. CBD provides no psychoactive effect.

Image source: Getty Images.

The allure of CBD is threefold. First, since it's a nonpsychoactive cannabinoid, it should appeal to a greater percentage of the population than products that contain THC. This makes it ideal to attract consumers who may not otherwise try cannabis-like products.

Secondly, CBD is almost always infused in derivative products (derivative meaning some other form of consumption beyond dried cannabis flower). Derivatives, such as vapes, edibles, infused beverages, topicals, and concentrates, almost always have considerably higher margins than THC-rich dried cannabis flower, which makes these products essential to the financial well-being of marijuana companies.

Third and finally, there are those aforementioned growth prospects. A recently released report from the Brightfield Group is calling for $23.7 billion in U.S. CBD sales by 2023, representing a compound annual growth rate from 2018 of (drumroll) more than 100%! That's leaps and bounds ahead of the general growth rate of the global cannabis industry, making CBD one of the hottest investment trends.

Unfortunately, CBD may not be the sure thing that every investors believes it'll be -- at least in the United States.

Image source: Getty Images.

The FDA "shows its cards" on CBD, and no one should be surprised

The one thing standing between CBD and perceived greatness is the U.S. Food and Drug Administration (FDA). And this past Monday, the regulatory agency showed its hand on CBD for the entire country, and investment community, to see.

On Monday, July 22, the FDA sent a warning letter to Curaleaf Holdings (NASDAQOTH: CURLF) CEO Joseph Lusardi letting him know that his company's CBD products, including its lotions, pain-relief patches, tinctures, and vape pens, were all "misbranded drugs" that were being sold in violation of the Federal Food, Drug, and Cosmetic Act. The FDA also flagged its Bido CBD products for pets as being unapproved and unsafe.

More specifically, the FDA wrote that Curaleaf is "illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products treat cancer, Alzheimer's disease, opioid withdrawal, pain and pet anxiety, among other conditions or diseases."

As a result of this warning letter, which will require Lusardi's response to correct these deficiencies within 15 days, Curaleaf lost its topical partnership with pharmacy giant CVS Health (NYSE: CVS). As a reminder, CVS Health announced in March that it would carry Curaleaf's topical products in roughly 800 of its stores in eight states, with CBD expected to be a means for low-margin pharmacy chains to drum up foot traffic to their stores. It's unclear if CVS will look elsewhere for its CBD supplies, especially with Walgreens Boots Alliance and Rite Aid following suit with cannabis products in their own stores shortly after CVS.

Image source: GW Pharmaceuticals.

With Curaleaf becoming the first multistate CBD provider to draw the ire of the FDA, it's crystal clear that the agency, which is currently reviewing CBD and has recently promised to expedite a report detailing its progress by either late summer or early fall, has little understanding of its benefit-versus-risk profile.

Let's remember that although the FDA approved GW Pharmaceuticals' (NASDAQ: GWPH) CBD-based oral solution known as Epidiolex in June 2018 for the treatment of two rare forms of childhood-onset epilepsy, these two indications are the only ailments the FDA views as benefiting from cannabis and its cannabinoids, period. Even with numerous positive (but correlative, not conclusive) university-level studies, the FDA does not view cannabis or CBD as being medically beneficial. That makes additives to food, beverages, and dietary supplements, as well as claims of certain medical benefit, big no-nos in the FDA's eyes.

And take note of what acting FDA chief information officer, Dr. Amy Abernethy, had to say in tweets just two weeks ago. While noting the need for the FDA to expedite its review process given the proliferation of CBD in various derivative products, she notes the "need to balance safety," and points out that the agency will merely be highlighting its progress, not necessarily making any conclusive findings or laying out CBD regulations as they pertain to food, beverages, and dietary supplements.

Image source: Getty Images.

What now for CBD stocks?

While the FDA's harsh stance on CBD is bound to disappoint investors, it's really no surprise given the agency's tough stance on cannabis.

As some of you may recall, the U.S. Drug Enforcement Agency had the opportunity to potentially reschedule or deschedule marijuana a few years ago, but chose not to change the federal classification on the drug. Part of this decision took into account the opinion of the FDA, which at the time noted that there were no official medical benefits of cannabis (albeit there are two now via GW Pharmaceuticals' Epidiolex), and that well-designed studies would need to be run to establish a true safety profile for marijuana. We've known for years where the FDA stood on pot, so its decision to get harsher with medical claims on CBD products shouldn't surprise anyone.

The big question that's left to be answered is: What will the FDA ultimately do following its update in a few months? One of the growing rumors is that the regulatory agency may approve limited or small quantities of CBD to be used in food, beverages, and dietary supplements while long-term studies are conducted. Such a move would allow CBD companies to get their feet in the door, so to speak, but the FDA's stringent policy would put a ceiling on near-term sales, as well as continue to limit medical claims for CBD, which could adversely impact its attractiveness to consumers not looking for a buzz.

Although I continue to view CBD stocks as an intriguing long-term investment opportunity, the FDA's governance of the ongoing rollout of product cannot be overlooked, and that's something investors need to keep in mind.

Sean Williams owns shares of CVS Health. The Motley Fool recommends CVS Health. The Motley Fool has a disclosure policy.


More Related News

Hedge Fund Innovator Joseph Edelman Doubles Down on These 3 Biotech Stocks
Hedge Fund Innovator Joseph Edelman Doubles Down on These 3 Biotech Stocks

More than 500 biotech companies operate in the US, doing their part to make it the world's hub for innovation. Only about 20 of them turn a profit, though, highlighting the dangers of the biotech sector. High overhead, long research terms, and the uncertainties of clinical testing and regulatory approval all weigh on them, making biotech at once the riskiest and most potentially profitable of the stock market's segments.Enter Joseph Edelman. The hedge fund veteran started Perceptive Advisors back in 1999 with just $6 million, and his hedge has grown to hold over $5 billion in assets under management today. Edelman's fund's flagship, the Perceptive Life Sciences Fund, specializes in small-...

U.S. Shelves Plan to Sharply Cut Nicotine in Cigarettes
U.S. Shelves Plan to Sharply Cut Nicotine in Cigarettes

(Bloomberg) -- U.S. regulators are hitting the brakes on plans to force tobacco companies to drastically reduce addictive nicotine in cigarettes, retreating on an ambitious public-health initiative that comes amid increasing worry about nicotine use among young people.The Department of Health and Human

Influential U.S. doctors group calls for ban on vaping products
Influential U.S. doctors group calls for ban on vaping products
  • US
  • 2019-11-19 22:04:37Z

The American Medical Association (AMA) on Tuesday called for a total ban on all e-cigarette and vaping products that are not approved by the U.S. Food and Drug Administration as smoking cessation tools. The AMA is urging regulators and legislators at the state and local levels to ban the sale and distribution of all e-cigarette and vaping products, and stipulates that those products should only be available by prescription.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply


Top News: Economy